Salubris Biotherapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.salubrisbio.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 155
- Registration Number
- NCT06667960
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇧🇪UZ Ghent, Ghent, Belgium
Study of JK07 in Patients With Chronic Heart Failure
- Conditions
- Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 282
- Registration Number
- NCT06369298
- Locations
- 🇺🇸
Site 121, Alexander City, Alabama, United States
🇺🇸Site 130, Birmingham, Alabama, United States
🇺🇸Site 139, Birmingham, Alabama, United States
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Conditions
- Metastatic CancerSmall-cell Lung CancerUrothelial CarcinomaPancreatic AdenocarcinomaThyroid CancerTumor, SolidAdvanced Solid TumorNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckLuminal Breast Cancer
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 263
- Registration Number
- NCT05620134
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪UZA, Edegem, Belgium
🇧🇪UZ Ghent, Ghent, Belgium
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Registration Number
- NCT05322616
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Harvard Medical School/Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 14
- Registration Number
- NCT04210375
- Locations
- 🇺🇸
University of Arizona College of Medicine, Tucson, Arizona, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Harvard Medical School/ Massachusetts General Hospital, Boston, Massachusetts, United States